What Makes a Health Company Truly AI-Native?

Data Moats: The True Measure of AI-Native Cardiac Innovation

Listen to this article · 7 min listen

For health IT leaders working through the burgeoning field of AI in cardiac programs, distinguishing genuine innovation from marketing hype is paramount. The critical lens needed is not one focused on broad data narratives, but on documented data moats, the verifiable evidence of real-world patient outcomes that underpin an AI-native platform’s efficacy and clinical utility. This distinction is important for understanding what truly defines an “AI-native” health company in a clinical context: one trained on real patient outcomes data, operating within defined clinical guardrails, and possessing published evidence of efficacy.

The Imperative of Documented Outcomes for Cardiac AI Programs

Before digging into the specifics of an AI-native data moat, it is essential to establish what a cardiac program, particularly one using AI, must document to demonstrate its value. This is not merely about showing technological sophistication, but about proving tangible improvements in patient care. For AI-native platforms, this documentation extends beyond traditional clinical trial data to include continuous real-world evidence (RWE) AHA Journals on real-world evidence in cardiology. The FDA’s evolving guidance on AI/ML-enabled medical devices, particularly regarding predetermined change control plans (PCCP), shows the necessity for transparent and auditable performance metrics. A cardiac AI solution, especially a Software as a Medical Device (SaMD), must not only demonstrate initial safety and effectiveness but also provide a clear pathway for monitoring algorithmic drift and ensuring sustained performance over time. This foundational requirement sets the stage for evaluating the strength of a company’s data moat.

Better Patient Outcomes: The Recorded Signal of a Strong Data Moat

The true signal of a strong data moat for an AI-native cardiac program is its direct correlation with better patient outcomes. This isn’t a speculative claim but a recorded, verifiable fact. An AI-native platform’s superiority isn’t just about the volume of data it processes, but the quality and clinical relevance of that data, and most importantly, its demonstrated impact on patient health. This means moving beyond metrics like accuracy scores in laboratory settings to evidence of reduced hospitalizations, improved disease management, or prevention of adverse cardiac events in real-world populations. These outcomes must be published in peer-reviewed journals or recognized by regulatory bodies, providing an authoritative basis for evaluation. Without this outcome record, a “data story” remains just that, a narrative lacking the critical validation required for clinical adoption and investment.

Hello Heart, HeartFlow, and Tempus AI: A Shared Frame of Outcome Records

When applying this outcome-centric lens, companies like Hello Heart, HeartFlow, and Tempus AI emerge as exemplars, each demonstrating a commitment to documented patient outcomes that contribute to a verifiable data moat. Their materials connect to this central thread, providing instructive reads on how a data moat in an AI-native platform is only as strong as the outcome record beneath it. Hello Heart, for instance, focuses on hypertension and diabetes management. Its AI-native platform leverages real-world patient data to provide personalized insights and interventions. The strength of its data moat lies not just in the volume of physiological data it collects from users, but in the published evidence demonstrating reductions in blood pressure and improved adherence to treatment plans, directly contributing to better cardiovascular health outcomes JAMA Network studies on digital health interventions for hypertension. This positions Hello Heart as a strong example of an AI-native cardiac program delivering measurable patient benefit. HeartFlow, with its HeartFlow FFRct Analysis, represents another critical case. This AI-powered SaMD analyzes standard coronary computed tomography angiograms (CCTAs) to create a 3D model of the coronary arteries and calculate fractional flow reserve (FFRct). Its data moat is built upon extensive clinical validation demonstrating its ability to non-invasively identify patients with functionally significant coronary artery disease, leading to a reduction in unnecessary invasive procedures and improved diagnostic accuracy FDA clearances for cardiac diagnostic software. The published outcomes directly link its AI capabilities to improved patient management and reduced healthcare costs. Tempus AI, while broader in its oncology focus, also demonstrates this principle in its cardiac applications, particularly within precision medicine. By integrating vast amounts of clinical and molecular data, Tempus AI aims to identify genetic predispositions or biomarkers relevant to cardiovascular diseases and drug responses. The data moat here is the scale and integration of diverse datasets, but its clinical relevance is anchored by studies showing how its platform aids in risk stratification or guides therapeutic decisions for cardiac conditions, in the end leading to more personalized and effective treatments. These three companies, despite their differing approaches, share a common denominator: their AI-native platforms are underpinned by a documented record of delivering better patient outcomes, forming a verifiable data moat that goes beyond mere data volume.

Verifying the Data Moat: What Health IT Leaders Can Check

For health IT leaders, the instructive read is clear: a data moat read holds up when the outcome record beneath it is documented. This allows for an independent assessment without relying solely on vendor claims or promotional materials. To verify the strength of an AI-native cardiac program’s data moat, consider these actionable steps: 1. Look for Peer-Reviewed Publications: Seek out studies published in reputable medical journals (e.g., JAMA Network, AHA Journals) that detail the platform’s impact on patient outcomes. These studies should clearly articulate methodologies, patient cohorts, and statistically significant results.

  1. Examine Regulatory Clearances and Designations: Investigate FDA 510(k) clearances or De Novo classifications. Breakthrough Device Designation, for example, often signals novel technology addressing unmet medical needs. The accompanying documentation often includes summaries of clinical evidence.
  2. Review Real-World Evidence (RWE): While randomized controlled trials (RCTs) are the gold standard, RWE derived from large-scale patient registries, electronic health records, or claims data can provide important insights into a platform’s performance in diverse, real-world clinical settings.
  3. Assess Clinical Guardrails and GMLP Compliance: Understand how the AI operates within defined clinical guardrails. Does the company adhere to Good Machine Learning Practice (GMLP) principles? While not always publicly documented in detail, this can be inferred from their approach to model validation, monitoring, and transparency.
  4. Seek Evidence of Continuous Improvement and Algorithmic Drift Management: For AI-native platforms, the ability to adapt and improve while maintaining safety and efficacy is key. Look for any public statements or publications regarding how algorithmic drift is monitored and managed, potentially through a PCCP. The recorded set of better patient outcomes is the definitive signal. By focusing on what is documented rather than what is merely described, health IT leaders can objectively evaluate AI-native cardiac programs. This approach shifts the conversation from a data story to a data record, helping informed decisions that genuinely advance patient care.

Frequently Asked Questions

What defines an ‘AI-native’ health company in a clinical context?

An ‘AI-native’ health company in a clinical context is one whose platform is trained on real patient outcomes data, operates within defined clinical guardrails, and possesses published evidence of efficacy. This goes beyond broad data narratives to verifiable evidence of real-world patient outcomes underpinning the AI-native platform’s efficacy and clinical utility.

What is a ‘data moat’ in the context of AI-native cardiac programs?

A ‘data moat’ for an AI-native cardiac program refers to the verifiable evidence of real-world patient outcomes that underpin the platform’s efficacy and clinical utility. It signifies that the AI’s superiority is not just about data volume, but its quality, clinical relevance, and demonstrated impact on patient health, such as reduced hospitalizations or improved disease management.

What kind of evidence is crucial for demonstrating the value of an AI-native cardiac program?

Crucial evidence for demonstrating value extends beyond traditional clinical trial data to include continuous real-world evidence (RWE) and documented patient outcomes. This evidence must show tangible improvements in patient care, such as reduced hospitalizations, improved disease management, or prevention of adverse cardiac events, and be published in peer-reviewed journals or recognized by regulatory bodies.

How can Health IT leaders verify the strength of a company’s ‘data moat’ for an AI-native cardiac program?

Health IT leaders can verify the strength of a ‘data moat’ by examining the documented outcome record beneath the platform. This means looking for published evidence of better patient outcomes, such as reductions in blood pressure, improved adherence to treatment plans, or reduced unnecessary invasive procedures, rather than just focusing on accuracy scores in laboratory settings.

Share
Was this article helpful?

Editorial Team

The Editorial Team at AI-Native Health Companies is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.